Navigation Links
The Italian Institute of Prophylaxis against Animal Diseases (IZS) to test effectiveness of BeesFree Inc.'s Technology in Combating Colony Collapse Disorder
Date:5/2/2012

WEST PALM BEACH, Fla., May 2, 2012 /PRNewswire/ -- BeesFree, Inc. (OTCBB: BEES), a company which owns patent pending technology that arrests the effects of CCD (Colony Collapse Disorder) on honeybees, announced that the Italian Experimental and Animal Prophylaxis Institute (IZS - Istituto Zooprofilattico Sperimentale) will be conducting an extensive laboratory and field project to test the effectiveness of BeesFree Inc.'s patent-pending technology.

IZS is a government agency operating within the framework of the National Health Service and has the mandate to research innovative solutions to improve animal health, welfare and food safety. IZS also provides services in the diagnosis of animal diseases, and the microbiological, chemical and physical controls over food safety, food production chains and animal feed.

BeesFree Inc. Chief Scientist and inventor of the patent-pending technology, Dr. Francesca del Vecchio, stated, "We believe this study, once completed, will confirm to beekeepers what we already know, that our proprietary chemical compound and delivery technology can effectively improve the health of honeybees and help them mitigate and avoid the effects of CCD. We greatly value our relationship with IZS and look forward to extending this cooperation agreement to cover other solutions relating to the health of honeybees."

IZS Director General, Dr. Remo Rosati stated, "IZS is proud to be associated with BeesFree and test in Italy its novel and innovative patent-pending technology to remedy CCD-related effects. We have allocated a strong team of senior chemical engineers, biologists and veterinaries for the laboratory and field test activities which will be carried out in the framework of this project. We hope this project will significantly contribute to improve our knowledge of effective solutions for honeybee health."

About BeesFree, Inc. (OTCBB:BEES)

BeesFree Inc., a company focused on developing innovative solutions for the global beekeeping community, owns a patent pending technology that helps honeybees mitigate and avoid the effects of Colony Collapse Disorder (CCD).  For more information please visit www.beesfree.biz or contact the company at the numbers listed below.

Forward-Looking Statements

Statements about the future expectations of BeesFree, Inc. and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as that term is defined in the Private Securities Litigation Reform Act of 1995. BeesFree, Inc. intends that such forward-looking statements shall be subject to the safe harbors created thereby. Since these statements involve certain risks and uncertainties and are subject to change at any time, Bees Free actual results could differ materially from expected results.


'/>"/>
SOURCE BeesFree, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses
2. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
3. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
4. CTI Seeks Strategic Alternative for Italian Facility
5. Richard H. Scheuermann, Ph.D. Joins J. Craig Venter Institute as Director of Informatics
6. Riordan Clinic Research Institute Has Developed and Patented a Process for the Assessment of the Energy Metabolism in Patients with Chronic Fatigue Syndrome
7. Harvards Wyss Institute creates living human gut-on-a-chip
8. Profil Institute Continues to Publish New Findings in Metabolic Research
9. Space Research Institute Honors Senator Hutchison with Pioneer Award
10. Camelot Healthcare Training Institute Acquired by Medtech
11. Genetics Policy Institute (GPI) Files Additional Legal Arguments in Sherley v. Sebelius Stem Cell Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
Breaking Biology Technology:
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):